Masahiro Kogami

Masahiro Kogami

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2022 in Rheumatology
Verified
Journal Article
Closed access
PDF file
MKMasahiro Kogami
Masahiro Kogami
YAYoshiyuki Abe
Yoshiyuki Abe
TATaiki Ando
Taiki Ando
AMAyako Makiyama
Ayako Makiyama
KYKen Yamaji
Ken Yamaji
NTNaoto Tamura
Naoto Tamura
Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) is characterised by rapidly progressive interstitial lung disease and has a poor prognosis. We aimed to investigate whether anti-MDA5 antibody titres and cytokine levels predict clinical course, and evaluate changes in both parameters before and after diagnosis. This was a retrospective, single-centre study in 38 patients with anti-MDA5 antibody-positive DM. We compared clinical characteristics and laboratory data at diagnosis between patients in the treatment response (n = 23) and non-response (n = 15) groups, and between those in the relapse (n = 5) and non-relapse (n = 24) groups. We also measured serum anti-MDA5 antibody titres and cytokine levels before and after diagnosis. The non-response group was older, had a higher ground-glass opacity score, lower PaO2/FiO2, higher C-reactive protein (CRP) level, and higher anti-MDA5 antibody titre than the response group. No cytokines significantly differed between groups at diagnosis. The relapse group had a significantly higher anti-MDA5 antibody titre than the non-relapse group. In the survivor group, the anti-MDA5 antibody titre and levels of interferon (IFN)-α, IFN-γ, monocyte chemotactic protein-1 (MCP-1), interleukin (IL)-6, IL-33, CRP, and ferritin were significantly lower 6 months post-treatment than at diagnosis. Macrophage-associated cytokines such as IL-6, IL-8, IL-18, and MCP-1 increased after anti-MDA5 antibody positivity in three patients who were anti-MDA5 antibody-positive before diagnosis. The anti-MDA5 antibody titre at diagnosis may predict the clinical course. Levels of macrophage-associated cytokines significantly declined at 6 months post-treatment, and they may have increased after anti-MDA5 antibody titre positivity.

13 February 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MKMasahiro Kogami
Masahiro Kogami
YAYoshiyuki Abe
Yoshiyuki Abe
TATaiki Ando
Taiki Ando
AMAyako Makiyama
Ayako Makiyama
KYKen Yamaji
Ken Yamaji
NTNaoto Tamura
Naoto Tamura
IgG4-related disease (IgG4-RD) was recently described in Japan. It is characterised by extensive organ involvement with tissue fibrosis. We assessed the performance of the 2019 American College of Rheumatology and European League Against Rheumatism (ACR/EULAR) classification criteria and the 2020 revised comprehensive diagnostic (RCD) criteria as well as differences between patients with and without IgG4-RD. In this retrospective, single-centre study of 50 patients admitted with suspected IgG4-RD, we evaluated the sensitivity and specificity of both criteria. We also compared clinical characteristics and laboratory data of patients with IgG4-RD (n = 42) and patients without IgG4-RD (n = 8). The ACR/EULAR classification criteria had 88.1% sensitivity and 87.5% specificity for IgG4-RD diagnosis. The RCD criteria had 100% sensitivity and 50% specificity. Patients with IgG4-RD had significantly more affected organs (p = 0.002). Patients with a single affected organ and IgG4-RD had significantly higher serum IgG4/IgG ratios (p = 0.027), lower serum C-reactive protein levels (p = 0.020), and lower total haemolytic complement activity (p = 0.044) than those without IgG4-RD. The ACR/EULAR classification criteria have high specificity and the RCD criteria have high sensitivity for diagnosing IgG4-RD. The number of affected organs is important for diagnosing IgG4-RD.

22 April 2023 in Rheumatology
Verified
Journal Article
Closed access
PDF file
YAYoshiyuki Abe
Yoshiyuki Abe
KMKentaro Minowa
Kentaro Minowa
MKMasahiro Kogami
Masahiro Kogami
TATaiki Ando
Taiki Ando
AMAyako Makiyama
Ayako Makiyama
NTNaoto Tamura
Naoto Tamura
Yoshiyuki Abe, Kentaro Minowa, Masahiro Kogami, Taiki Ando, Ayako Makiyama, Ken Yamaji, Naoto Tamura; Avacopan is possibly associated with the improvement of AN

15 June 2023 in Modern Rheumatology Case Reports
Verified
Journal Article
Open access
PDF file
AMAyako Makiyama
Ayako Makiyama
YAYoshiyuki Abe
Yoshiyuki Abe
HFHoshiko Furusawa
Hoshiko Furusawa
MKMasahiro Kogami
Masahiro Kogami
TATaiki Ando
Taiki Ando
NTNaoto Tamura
Naoto Tamura
In response to the coronavirus disease 2019 pandemic, the coronavirus disease 2019 vaccine was rapidly developed and the effectiveness of the vaccine has been established. However, various adverse effects have been reported, including the development of autoimmune diseases. We report a case of new-onset polyarteritis nodosa in a 32-year-old male following the coronavirus disease 2019 vaccination. The patient developed limb pain, fever, pulmonary embolism, multiple subcutaneous nodules, and haematomas. Skin biopsy revealed necrotising inflammation accompanied by fibrinoid necrosis and high inflammatory cell infiltration in the walls of medium to small arteries. The symptoms resolved following corticosteroid treatment. Although it is difficult to prove a relationship between the vaccine and polyarteritis nodosa, similar cases have been reported and further reports and analyses are therefore necessary.

25 July 2025 in Modern Rheumatology Case Reports
Verified
Journal Article
Closed access
MKMasahiro Kogami
Masahiro Kogami
RTRina Takahashi
Rina Takahashi
RSRyosuke Shirayanagi
Ryosuke Shirayanagi
WNWataru Nakamura
Wataru Nakamura
TSTakumi Saito
Takumi Saito
NTNaoto Tamura
Naoto Tamura
Pustulotic arthro-osteitis (PAO) is an inflammatory osteoarticular disorder associated with palmoplantar pustulosis (PPP). Whilst anti-TNF-α agents and IL-23 inhibitors have shown efficacy in PAO, the therapeutic potential of bimekizumab (BKZ), a dual IL-17A and IL-17F inhibitor, remains unestablished. A 53-year-old Japanese man with a history of PPP developed fever and polyarthritis involving the distal interphalangeal joints, shoulders, and knees. Laboratory investigations revealed elevated inflammatory markers, including C-reactive protein and matrix metalloproteinase-3. Imaging studies showed inflammation of the sternum and sacroiliac joints, consistent with PAO. Despite treatment with nonsteroidal anti-inflammatory drugs, methotrexate, adalimumab, and upadacitinib, his symptoms and systemic inflammation persisted. Bacterial cultures were negative, and no other causes of fever were identified. The patient became afebrile the day after switching to BKZ, and both joint and skin symptoms gradually improved thereafter, along with normalisation of laboratory markers. This case highlights the potential utility of BKZ in the treatment of refractory PAO, particularly in cases with systemic inflammation and fever.

14 June 2025 in Rheumatology
Verified
Journal Article
Closed access
MTMotoki Takeuchi
Motoki Takeuchi
YAYoshiyuki Abe
Yoshiyuki Abe
MKMasahiro Kogami
Masahiro Kogami
AMAyako Makiyama
Ayako Makiyama
KYKen Yamaji
Ken Yamaji
NTNaoto Tamura
Naoto Tamura